Neutrophil Extracellular Traps
==============================

The formation of neutrophil extracellular DNA traps (so called NETs) was first recognized as a host innate immune defense mechanism against infections by [@B10]. This discovery altered the fundamental conception of the innate immune function of phagocytes against pathogenic microbes in a most fascinating way. Whereas it was previously believed that neutrophils kill invading pathogens by intracellular uptake (phagocytosis) and subsequent killing, the discovery of NETs revealed an additional phagocytosis-independent mechanism. The released nuclear material including histones and DNA within the extracellular trap (ET) immobilize and occasionally kill several medically important bacteria, viruses, or parasites ([@B10]).

Regarding the cellular pathways that lead to NET formation, most studies show that the cell in question undergoes NETosis, a process of death that differs morphologically from necrosis and apoptosis ([@B27]). In contrast to apoptotic or necrotic cells, cells that undergo NETosis show a prelytic decondensation of the chromatin associated with the disruption of the nuclear membrane. This disintegration of the nuclear membrane allows mixing of DNA and histones with granule components, which are then extracellularly released as web-like fibers with a diameter of approximately 15 to 17 nm, associated with globular proteins or antimicrobial peptides. NET-based antimicrobial activity remains active when cells are treated with the actin microfilament inhibitor cytochalasin D, indicating that this phenomenon is independent of phagocytosis. However, the antimicrobial activity of NETs can be abolished when NETs are treated with DNase, confirming that DNA comprises the functional backbone of the released fibers ([@B10]; [@B27]).

The formation of NETs was initially thought to be an antimicrobial defense strategy and cell death pathway specific for neutrophils ([@B10]). However, [@B70] mast cells were shown to also deploy mast cell extracellular traps (MCETs) in defense against bacterial pathogens. During recent years, further evidence has accumulated demonstrating ET formation occurs in eosinophils ([@B76]), basophils ([@B60]), fibrocytes ([@B39]), macrophages ([@B5]; [@B16]), and monocytes ([@B5]; [@B16]).

It is important to mention that some authors have demonstrated experimentally that eosinophils and neutrophils can release antimicrobial ETs in response to infection while remaining in a viable status ([@B76], [@B77]). NET release by viable cells was confirmed *in vivo* in a murine model of *Staphylococcus aureus* skin infection ([@B74]). Here, NET formation was seen as a dynamic process, which occurs by vesicular release of nuclear material during migration of neutrophils through the tissue. It is still unclear, however, how such budding and final release of nuclear material is initiated. Thus, based on current knowledge it seems that at least two different mechanisms can lead to NET formation: a viable form involving vesicular release and the more well-understood NETosis form associated with rupture of the nuclear membrane. Research has begun to explore how certain drugs, including statins ([@B16]) and tamoxifen ([@B19]), modulate neutrophil functions to accentuate NET formation, which could be beneficial as an adjunctive therapy for extracellular pathogens such as *S. aureus* that efficiently avoid phagocytic killing by neutrophils.

In contrast to their protective effect against several infections, there is increasing evidence that a dysregulated NET release can provoke autoimmune reactions, tissue damage and impaired cellular functions ([@B68]; [@B56]). Unchecked, aberrant NET formation can result in pathological damage as vascular thrombosis ([@B28]) or chronic lung inflammation in cystic fibrosis ([@B49]). Countermeasures to the excessive NET formation may be of therapeutic utility in such cases as for example DNAse treatment in patients with cystic fibrosis ([@B26]) or the usage of anti-histone antibodies to alleviate vascular thrombosis ([@B61]). Since sustained blockade of NET formation may carry a risk of increased susceptibility to certain infections, anti-NET therapy might be targeted to severe autoimmune or inflammatory diseases, when pro-inflammatory activities of NETs outweigh their protective benefits ([@B57]).

The Role of NETs Against Infection
==================================

In several studies, NETs were found to play a protective role against various infecting organisms, often employing mutagenesis of key evasion factors of the respective organisms. It is thought that NETs can act in two ways: (1) pathogen immobilization and (2) growth inhibition or killing of the microbe. The relative importance of killing is a point of some contention in the literature ([@B43]). However, based on vital immunofluorescent staining of bacteria with DNA intercalating dyes, microbial killing by NETs has been demonstrated definitively by several authors ([@B41]; [@B9]; [@B34]). However, since the overall killing potential of NETs is physically restricted, the cumulative effect of NETs may be functionally bacteriostatic ([@B6]).

Because some bacteria have evolved highly efficient resistance strategies against antimicrobial activity of NETs, in some specific circumstances, NETs can help to establish an infectious niche. For example, in the case of a primary influenza A infection of the middle ear which boosts formation of NETs by infiltrating neutrophils, resistant *Streptococcus pneumoniae* can use those NETs to multiply and persist in the middle ear cavity ([@B64]). Additionally, some studies show that *S. pneumoniae* and *Haemophilus influenzae* can incorporate NETs into biofilms that promote their persistence in the host ([@B36]; [@B54]). In the end, it depends on the pathogen, its array of immune resistance factors and the anatomical site of infection, as to whether NETs can serve a protective function for the host during an infection (**Figure [1](#F1){ref-type="fig"}**).

![**Extracellular trap formation during infections: consequences for the host.** The figure summarizes the protective versus detrimental role of NETs for the host during an infection with respective pathogens. In some cases (highlighted with an asterisk), there is benefit and harm depending on site, timing and magnitude of infection. The immunofluorescence micrograph is showing the release of NETs from human blood-derived neutrophils. NETs were stained with antibodies against histone-DNA complexes (green) and DAPI to stain the nuclei and nuclear DNA (blue).](fmicb-07-00402-g001){#F1}

Categories of Bacterial NET Evasion Factors
===========================================

Neutrophil extracellular trap evasion factors can be classified in three different phenotypes: (1) NET degradation, (2) resistance to the intrinsic antimicrobial effectors within NETs, or (3) the suppression of NET production ([@B69]). The best-studied NET evasion factor is the activity of microbial nucleases that degrade NETs deployed by innate immune cells to escape entrapment. Membrane-bound or released nucleases have been shown to be expressed by the following microbes as NET evasion factors: *Aeromonas hydrophila* ([@B12]), *Escherichia coli* ([@B45]), *Leptospira* sp. ([@B59]), *Neisseria gonorhoeae* ([@B38]), *S. aureus* ([@B9]), *S. agalactiae* ([@B21]), *S. pneumoniae* ([@B8]), *S. pyogenes* ([@B13]; [@B15]), *Streptococcus synguinis* ([@B46]), *S. suis* ([@B20]), *Vibrio cholera* ([@B62]), and *Yersinia enterocolitica* ([@B45]). Whereas, resistance to antimicrobial effectors in ETs is mainly mediated by surface-bound virulence factors, e.g., exopolysaccharide capsules in case of *S. pyogenes* ([@B18]) or *S. pneumonia* ([@B72]), the suppression of NET formation is mainly carried out by released factors including proteases ([@B78]).

Bacterial Exotoxins that Modulate NET Formation
===============================================

During the last 10 years, there is increasing evidence in the literature that different exotoxins released by Gram-positive or Gram-negative bacteria are able to modulate the process of NET formation (**Table [1](#T1){ref-type="table"}**): to date, at least 11 different exotoxins have been published to modulate NET formation, with nine of them reported to enhance NET formation while two suppress the process (**Table [1](#T1){ref-type="table"}**). First we will set our attention on those toxins that induce NET formation.

###### 

Effect of bacterial exotoxins on formation of extracellular traps.

  Microbe                        Exoprotein                           Effect on cells                                                                                   Mechanism                                                           Cell death                                        Putative consequences for the host                                        Reference
  ------------------------------ ------------------------------------ ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------- ----------------
  *Bordetella pertussis*         Adenylate cyclase toxin (ACT)        Suppression of NET formation and apoptosis                                                        Generation of cAMP and inhibition of oxidative burst                Impairment of cell lysis                          ACT promotes neutrophil infiltration by inhibiting neutrophil death       [@B24]
  *Escherichia coli*             Hemolysin                            Induction of ETs in murine and human macrophages                                                  Not known                                                           Not known                                         Not known                                                                 [@B2]
  *Mannheimia haemolytica*       Leukotoxin                           Induction of ETs in bovine neutrophils, as well as bovine, murine, and human macrophages          CD18- and NADPH-oxidase dependent                                   Delayed LDH release, no necrosis, no aptoptosis   Trapping and killing of *M. haemolytica*                                  [@B3], [@B2]
  *Mycobacterium tuberculosis*   Early secretory antigen-6 protein    Induction of secondary necrosis and ET formation of phosphatidylserine externalized neutrophils   Intracellular Ca^2+^ overload                                       Cell lysis                                        Necrotic granulomas during tuberculosis                                   [@B25]
  *Pseudomonas aeruginosa*       Pyocyanin                            Induction of NETs                                                                                 NADPH- oxidase- and Jun N-terminal kinase-dependent                 Cell lysis                                        Inflammatory condition during cystic fibrosis                             [@B51]
  *Staphylococcus aureus*        N-terminal ArgD peptides             Induction of NETs                                                                                 Unknown                                                             Cell lysis                                        Aggravation of skin lesions                                               [@B31]
  *Staphylococcus aureus*        Leukotoxin GH                        Induction of NETs                                                                                 Non-specific cytolysis                                              Non-specific cytolysis                            Entrapment of *S. aureus*                                                 [@B42]
  *Staphylococcus aureus*        Panton-Valentin-leukocidin           Induction of rapid nuclear NET formation                                                          Vesicular release of nuclear DNA, independent of NADPH- oxidase     No cell lysis                                     Entrapment of *S. aureus*                                                 [@B50]
  *Staphylococcus epidermidis*   Phenol-soluble-modulin γ (δ-toxin)   Induces NET formation and colocalizes with NETs and host antimicrobial peptides                   Physically binding to host derived antimicrobial peptides and DNA   Cell lysis                                        Cooperates with host antimicrobial peptides against bacterial pathogens   [@B17]
  *Streptocococus pyogenes*      M1 protein                           Induces formation of NETs and MCETs                                                               Unknown                                                             Cell lysis                                        Trapping and killing of *S. pyogenes*                                     [@B41]; [@B48]
  *Streptocococus pyogenes*      Streptolysin O                       Suppression of NET formation                                                                      Impairment of oxidative burst                                       Sublytic con-centrations                          Severe infection                                                          [@B66]

The M1-protein of the Gram-positive bacterium *S. pyogenes*, also known as group A *Streptococcus* (GAS), was the first exotoxin described to induce formation of ETs by neutrophils and mast cells ([@B41]). The surface-anchored M1 protein is a classical virulence factor that promotes resistance to phagocytosis. However, after proteolytic release from the *S. pyogenes* surface, the M1 protein forms a proinflammatory supramolecular network with fibrinogen that contributes to the pathophysiology of streptococcal toxic shock-like syndrome ([@B35]). Two parallel studies showed in 2009, that the M1 protein is able to mediate formation of NETs as well as MCETs, and thereby contribute to entrapment and killing of the bacteria ([@B41]; [@B48]). Besides induction of ETs, M1 protein promotes resistance to the human cathelicidin antimicrobial peptide LL-37, an important effector of bacterial killing by neutrophils and mast cells ([@B41]; [@B40]).

*Staphylococcus epidermidis* is a common colonizer of healthy human skin and is hypothesized to play a mutually beneficial role in the cutaneous niche. [@B17] demonstrated that *S. epidermidis* phenol-soluble-modulin γ (δ-toxin) boosts NET production and further colocalizes with endogenous host antimicrobial peptides within the architecture of the expressed NETs. In antimicrobial assays against the pathogen *S. pyogenes*, δ-toxin cooperated with host-derived antimicrobial peptides cathelicidins (human LL-37 and murine CRAMP) and human beta-defensins (hBD2 and hBD3) to kill the pathogenic streptococci. Coimmunoprecipitation and tryptophan spectroscopy demonstrated direct binding of δ-toxin to LL-37, CRAMP, hBD2, and hBD3, as well as DNA. These data suggest that commensal *S. epidermidis*-derived δ-toxin cooperates with the host-derived antimicrobial peptides in the innate immune system to reduce survival of an important human bacterial pathogen. This could be corroborated in a mouse wound model where *S. pyogenes* survival was reduced when the wounds were pretreated with δ-toxin. These data described a novel therapeutic application of a bacterial toxin against pathogenic bacteria to enhance formation of NETs and support the host innate immune system.

*Mannheimia haemolytica* leukotoxin (LKT) induces formation of extracellular traps in bovine neutrophils and macrophages ([@B3], [@B2]). LKT is a member of the repeats-in-toxin (RTX) family of exoproteins produced by a wider variety of Gram-negative bacteria. In addition to the native fully active LKT, its non-cytolytic pro-LKT precursor also stimulated macrophage extracellular traps (METs) formation. Formation of METs in response to LKT required NADPH oxidase activity, as previously demonstrated for NETosis. METs induced in response to LKT trapped and killed a portion of the toxin-producing *M. haemolytica* cells. In contrast to NETosis, which is reported to occur between 10 min to 4 h after pathogen exposure, LKT-induced MET formation was extremely rapid, with significant accumulation of extracellular DNA within 2 min after macrophage stimulation.

Interestingly, the LKT-mediated cytotoxic effects are specific to ruminants, since LKT binds to amino acids 5--17 of the signal sequence of CD18, which is not present on mature leukocytes from humans and other mammalian species ([@B63]). CD18 was confirmed by [@B3] to play a role in LKT-dependent NET formation in bovine phagocytes. Similarly, to the LKT, the related RTX family toxin, uropathgenic *E. coli* (UPEC) hemolysin, induced NET formation in the mouse and human monocyte/macrophage cell lines indicating that NET induction may be a general phenomenon in response to active RTX toxins ([@B2]). At this point it remains difficult to assess whether NET production in response to RTX toxins leads to a protective host defense against *M. haemolytica* or other Gram-negative bacteria. In the case of LKT, bacterial cells entrapped in NETs can continue to secrete LKT, an important virulence determinant, which could exacerbate lung inflammation ([@B3], [@B2]).

The *Pseudomonas aeruginosa* virulence factor pyocyanin stimulates the release of NETs in a NADPH oxidase-dependent manner ([@B51]). Pyocyanin is a redox-active pigment associated with diminished lung function in cystic fibrosis. In cystic fibrosis airways, *P. aeruginosa* resides in biofilms protected from neutrophil phagocytic activity or from entrapment by NETs ([@B51]). The authors speculate that enhanced ROS-dependent NET formation by *P. aeruginosa* pyocyanin contributes to inflammatory conditions observed in chronically infected cystic fibrosis airways. Parenthetically, chronic granulomatous disease (CGD) patients, whose neutrophils are unable to make NETs, are not recognized to be disproportionately susceptible to infections with *Pseudomonas* species ([@B52]).

A specific activity of an exotoxin was shown for the *Mycobacterium tuberculosis* leukocidin ESAT-6, which induced NET formation only in a subpopulation of neutrophils with externalized phosphatidylserine as a marker for apoptosis ([@B25]). Thus, ESAT-6 induced NET formation was similar to secondary necrosis of pre-activated neutrophils and dependent on Ca^2+^. In this case, increased NET formation was also speculated to contribute to virulence of tuberculosis, since it was recently observed that the development of necrotic granulomas in a mouse model of progressive tuberculosis were associated with the presence of extracellular bacteria, neutrophil necrosis and NET-like structures ([@B25]).

In the case of the leading human pathogen *S. aureus*, three different exotoxins enhance the release of NETs: N-terminal AgrD peptides ([@B31]), leukotoxin GH ([@B42]), also known as LukAB ([@B22]), thus named here LukGH/AB, and Panton-Valentin leukocidin (PVL; [@B50]). AgrD is the precursor for the auto-inducing peptide in a well-known quorum sensing system regulating virulence phenotypes of *S. aureus*. A recent mass spectrometry-based study identified formylated and non-formylated peptide variants derived from AgrD N-terminal leader domain in *S. aureus* cell-free culture supernatant to act cytotoxic, modulate neutrophil chemotaxis and induce formation of NETs. As a consequence a detrimental effect for the host was hypothesized as indicated by aggravation of skin lesions *in vivo* in a murine model. The cellular pathways mediating this process of AgrD induced NET formation remain unclear ([@B31]).

*Staphylococcus aureus* LukGH/AB, also promotes formation of NETs in association with death of the neutrophil ([@B42]). LukGH/AB is a pore-forming cytolytic toxin with proinflammatory properties, similar to those established for PVL. But unlike PVL, LukGH/AB did not prime human neutrophils for increased production of reactive oxygen species nor did it enhance binding and/or uptake of *S. aureus*. LukGH/AB promoted the release of NETs, which in turn ensnared but did not achieve killing of *S. aureus*. These authors found that electropermeabilization of human neutrophils, used to create pores in the neutrophil plasma membrane, induced NET formation in a similar way. This finding indicated that NETs can be generated during non-specific cytolysis.

The above phenomemon stands in contrast to NET formation initiated by PVL production in *S. aureus*. [@B50] demonstrated a novel rapid (5--60 min) process of NET formation that did not require cell lysis or even breach of the plasma membrane. The authors show that neutrophils treated with *S. aureus* supernatant show rounded and condensed nuclei, followed by the separation of the inner and outer nuclear membrane and budding of vesicles filled with nuclear DNA. The vesicles are extruded intact into extracellular space where they rupture, release the chromatin and form NETs. PVL was identified as one key effector of NET formation present in the *S. aureus* supernatant, but other yet unidentified molecules aside from PVL cannot be excluded as contributors to NET production. This rapid process of NET formation against *S. aureus* was dubbed "dynamic NETosis" and was recently proven to serve as an efficient host defense strategy during *S. aureus* skin infections in man and mice ([@B74]). Since, PVL targets a different receptor on the neutrophil compared to the LukGH/AB, namely the C5aR receptor ([@B65]) and the CD11b receptor ([@B23]), respectively, it still remains to be determined if the receptor-mediated signaling leads to the different NET phenotypes.

Two toxins have been described so far to suppress NET formation, perhaps representing an immune evasion strategy by the respective pathogens: *Bordetella pertussis* adenylate cyclase toxin ([@B24]) and *S. pyogenes* streptolysin O (SLO; [@B66]). Both mechanisms are coupled to suppression of neutrophil oxidative burst. In case of *S. pyogenes* SLO, this mechanism plays a key role of SLO in the pathogen's resistance to immediate neutrophil killing. In case of *B. pertussis*, the relevance of NET inhibition by the toxin is still unclear, since it is not known whether or not NETs are able to entrap and clear *B. pertussis*. This study highlighted how convalescent phase serum from humans following clinical pertussis blocked the ACT-mediated suppression of NET formation ([@B24]). Based on this finding, the authors mention that their data should alert investigators to the ability for ACT, and antibodies to ACT, to dysregulate neutrophil death mechanisms and potentially influence local tissue damage during infection with *B. pertussis*.

Concluding Comments
===================

With increasing publications in the NET field it is well-known that NETs are on one hand protective against several infections, but may also result in detrimental effects when released in excessive amount. The complexity may be compared with the release of cytokines during infection and inflammation, which serve an essential role in an efficient immune response of the host against infections, but in which overwhelming cytokine storm can lead to septic shock and accelerate death of the host. The cumulative balance between NET formation and NET degradation -- similar to cytokine release -- defines the protective versus detrimental effects on the organism. Currently, it is under discussion in the literature if and how NETs can act as a novel therapeutic or prophylactic target for boosting immunity to bacterial infections or mitigating inflammatory diseases associated with detrimental NET formation. To rationally and effectively pharmacologically interfere with the process of NET formation, the cellular processes mediating this phenomenon need to be understood more in detail. Identification of bacterial factors, especially exotoxins, with specific roles in NET modulation, may serve as probes to understand the molecular basis of NET generation and antimicrobial activity. Furthermore, exotoxins might themselves harbor therapeutic potential when their effects against the host cells are fully characterized.
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